Skip to main content

Alzheimer's Disease clinical trials at UCSD
11 in progress, 5 open to eligible people

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

    open to eligible people ages 55-90

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

    La Jolla, California and other locations

  • Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

    open to eligible people ages 50-80

    The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

    San Diego, California

  • Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

    open to eligible people ages 55-85

    This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).

    La Jolla, California and other locations

  • Salsalate in Patients Mild to Moderate Alzheimer's Disease

    open to eligible people ages 50-85

    The purpose of the study is to test the safety and tolerability of twice daily Salsalate in patients with mild to moderate Alzheimer's Disease. Half of the participants will receive Salsalate and half will receive placebo during the 1-year duration of the study.

    San Diego, California and other locations

  • Study of BHV-4157 in Alzheimer's Disease

    open to eligible people ages 50-85

    Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.

    La Jolla, California and other locations

  • 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

    Sorry, in progress, not accepting new patients

    The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI]. Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities in progress.

    San Diego, California and other locations

  • A Study of Brain Aging in Vietnam War Veterans

    Sorry, not currently recruiting here

    Traumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat related problems and may be associated with a greater risk of Alzheimer's disease (AD). The purpose of this study is to examine the possible connections between TBI and PTSD, and the signs and symptoms of AD on Veterans as they age. The information collected will help to learn more about how these injuries may affect Veterans of the Vietnam War as they grow older, as well as Veterans of the current wars in Iraq and Afghanistan, who also have these types of combat related injuries.

    La Jolla, California and other locations

  • A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

    Sorry, in progress, not accepting new patients

    This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with prodromal Alzheimer's Disease. Participants will be randomized to receive subcutaneous (SC) injections of either gantenerumab or placebo. Participants who consent to be part of the sub study will undergo positron emission tomography (PET) scanning to assess brain amyloid. The anticipated time on study treatment is 104 weeks in Part 1, with an option for an additional up to 2 years of treatment in Part 2, followed by an open-label extension (Part 3) until July 2020. The dosing for Parts 1 and 2 was stopped after a planned futility interim analysis showed a low probability of meeting the primary outcome measure with the doses studied. The study has converted to open-label to investigate higher gantenerumab doses.

    La Jolla, California and other locations

  • A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease

    Sorry, in progress, not accepting new patients

    This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.

    La Jolla, California and other locations

  • Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

    Sorry, not currently recruiting here

    The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers. This study also offers an observational component collecting cognitive assessment data until the availability of an enrolling drug treatment group, referred to as cognitive run-in (CRI).

    La Jolla, California and other locations

  • Prazosin for Agitation in Alzheimer's Disease

    Sorry, not currently recruiting here

    The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion

    San Diego, California and other locations

Last updated: